A study by Professor Lichtenberg of Columbia University attributes up to 96% of the increase in life expectancy in cancer patients and a high degree of […]

Increased international competitiveness and digitalisation will require more investment in infrastructure and resources to ensure that our country remains at the forefront of biomedical R&D Source: […]

Farmaindustria explains to Esclerosis Múltiple Euskadi what these studies consist of, how to take part in them and how research into this pathology is progressing Source: […]

Aerospace and defence investment is eight times higher than in the aerospace and defence industry, seven times higher than in the chemical industry, and twice as […]

Oncology, infectious diseases, neurology, haematology and endocrinology are the areas with the highest number of clinical trials with new treatments underway. Seven out of ten molecules […]

Farmaindustria explains to some twenty experts some of the policies and initiatives that have made Spain an international benchmark in clinical drug trials Source: farmaindustria.es Representatives […]

Farmaindustria organises workshops with representatives of the Spanish Data Protection Agency and the Spanish Medicines Agency to continue working on the implementation of the new Code […]

In the framework of its General Assembly, held in Madrid Source: www.actasanitaria.com In the framework of its General Assembly, held in Madrid, Farmaindustria has highlighted, this […]

Representatives of patients’ associations, researchers and experts in health economics debate in the newspaper El Español on the link between health, the economy and the well-being […]

The creation of the European Health Data Space is emerging as a great opportunity to boost R&D for new medicines. Public-private collaboration, once again, at the […]

For the first time in the history of medicine a drug completely kills all patients’ tumours Source: www.larazon.es It’s called dostarlimab, it’s an experimental cancer drug, […]